News

CALL FOR PAPERS NOVEMBER 2024

IJSAR going to launch new issue Volume 05, Issue 11, November 2024; Open Access; Peer Reviewed Journal; Fast Publication. Please feel free to contact us if you have any questions or comments send email to: editor@scienceijsar.com

IMPACT FACTOR: 6.673

Submission last date: 15th November 2024

Determination of HIV-1 tropism. Roosevelt hospital, Guatemala

×

Error message

  • Notice: Trying to access array offset on value of type int in element_children() (line 6609 of /home1/sciensrd/public_html/scienceijsar.com/includes/common.inc).
  • Notice: Trying to access array offset on value of type int in element_children() (line 6609 of /home1/sciensrd/public_html/scienceijsar.com/includes/common.inc).
  • Deprecated function: implode(): Passing glue string after array is deprecated. Swap the parameters in drupal_get_feeds() (line 394 of /home1/sciensrd/public_html/scienceijsar.com/includes/common.inc).
Author: 
Jessenia Sabrina Navas Castillo, Maria Cristina Quintana Galindo, Nydia Anaidé Orózco Morán, Mircea Lisbeth Romero Trujillo, Corilia Sucely García Porres, Diana Karina Baldizón Pernillo, Verónica Lucía Patzán Guamuch, Rodolfo Pinzón Meza and Ana Johanna S
Page No: 
7411-7414

Objective: Establish the proportion of adult patients with multiple failures to antiretroviral therapy regimens who could benefit from the use of R5 antagonists by determining HIV-1 tropism. Methodology: Records of 42 HIV-1-positive adult patients treated at the "Dr. Carlos Rodolfo Mejía Villatoro" of the Roosevelt Hospital, who were instructed to perform a viral tropism test of the V3 hypervariable region of glycoprotein 120 by sequencing on the MiniSeq™ - Illumina system, using the DeepChek® v2.0 software, during the period from January 2018 to February 2021. Results: Of the 42 included records of patients for whom viral tropism testing was indicated, 50.0% were male. The median age at the time of the test request was 41 years (IQR 33.3, 45.8). 61.9% corresponded to co-receptor R5. Conclusion: The high proportion of R5 virus obtained by determining HIV-1 tropism in adult patients with multiple failures is similar to that reported in other studies. The performance of this test is necessary for a targeted and personalized treatment in which patients could benefit from the use of R5 antagonists.

Download PDF: